樂普生物(02157.HK)折讓近11%配售H股 淨籌逾4.6億元
樂普生物(02157.HK)公布,已於7月4日與配售代理訂立協議,計劃配售最多9,382.5萬股新H股,配售價每股5.02元,較前收市價5.64元折讓約10.99%。配售股份規模佔經擴大後全部已發行H股及全部已發行股本約5.36%及5.2%。
假設所有配售股份獲悉數配售,配售所得款項總額料為4.71億元,所得淨額約4.63億元。公司計劃將約20%用於核心產品MRG003(EGFR-ADC)的商業化及市場推廣;60%用於推進核心產品臨床試驗;其餘20%投入到新產品管線研發。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.